NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Jun 14 2021

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

This approval allows NATCO's marketing partner to launch the generic version of KYPROLIS in the U.S. market. The company expects to benefit from marketing exclusivity for certain strengths of the product upon launch. The press release also mentions a settlement agreement related to the product's litigation, allowing for a future launch date.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases